Genmab A/S – Weekly Performance and Market Impact

Share Price Momentum

On 30 October 2026, Genmab’s shares closed at 3 912 DKK, marking a 48 % gain over the preceding week. The record closing price reflects a sustained upward trend, with the stock ending the week at the top of its 52‑week range (high: 3 947 DKK). The daily increase on Friday was 3.3 %.

Drivers of the Rally

The sharp rise was primarily driven by positive clinical data for Genmab’s cancer drug portfolio. A recent pivotal trial achieved key endpoints, prompting the company to announce a record‑high share price and reinforcing confidence among investors.

Analyst Coverage

  • H.C. Wainwright upgraded its price target for the American listing from $42 to $70, representing a 36 % increase.
  • Morgan Stanley similarly raised its target price by 35 %, from $42 to $57, while maintaining a neutral recommendation.

These adjustments signal a reassessment of Genmab’s valuation in light of the trial results and the company’s broader pipeline prospects.

Market Context

The Danish equity market, as reflected by the C25 index, finished the week up by 0.1 %, underscoring a generally positive sentiment across Danish shares. While the broader market experienced modest gains, Genmab’s performance stood out as a leading contributor to the weekly upside.

Company Profile

Genmab A/S operates in the biotechnology sector, specializing in antibody therapeutics for cancer treatment. With a market capitalization of 226 350 000 000 DKK and a price‑earnings ratio of 26.56, the company is listed on the OMX Nordic Exchange in Copenhagen. Its operations and product development continue to attract significant investor interest, particularly following the latest clinical milestones.